journal article·2025-12Open access

Bioinformatics driven in gene targeting platform for gold anticancer strategy delivery

Can Jiang, Haixuan Wen, Jiabin Chen, Na Han, Xin Sun, Yuzhu Zhang, Yongbin Hu, Guang Shu, Gang Yin, Maonan Wang

Abstract

Owing to its high degree of malignancy and poor survival outcomes, triple-negative breast cancer (TNBC) is considered the most invasive subtype of breast cancer. In the realm of TNBC treatment, clinical practice continues to be predominantly characterized by the utilization of chemotherapy regimens. The development of anticancer therapies that are specifically targeted and precise in their action remains a significant challenge within this therapeutic domain. This study aims to discover new target genes and develop nucleic acid delivery systems. In this study, we identified the differentially expressed gene SDC1, which exhibited high levels of expression in TNBC and correlates with poorer overall survival trends through a comprehensive gene chip data screening analysis. The results of our analysis suggest a positive correlation between increased SDC1 expression levels and etoposide drug resistance in cases of TNBC. For mechanistic insights, scRNA-seq was employed to map SDC1-dependent alterations in the tumor microenvironment (TME) immune architecture. In view of this, the present study successfully constructed an in situ self-reactive gold nanocluster SDC1 shRNA-targeted nucleic acid delivery system in tumor cells by taking advantage of the reductive microenvironment at the tumor site, which significantly inhibited TNBC angiogenesis. This study elucidated the molecular mechanism by which SDC1 promotes tumor progression through multidimensional modulation of the TNBC microenvironment. It also proposed a bioinformatics-driven gene-targeting integrated platform for the rational design and delivery of gold nanocluster-based anticancer strategies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Gene expression and cancer classification · Advanced Biosensing Techniques and Applications · Genetics, Bioinformatics, and Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (77)

Show source-provided references
1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Pathological features and prognosis of different molecular subtypes of breast cancer10.3892/mmr.2012.981 ↗
3. Triple-negative breast cancer molecular subtyping and treatment progress10.1186/s13058-020-01296-5 ↗
4. Pathogenesis of triple-negative breast cancer10.1146/annurev-pathol-042420-093238 ↗
5. Molecular classification of breast cancer: relevance and challenges10.5858/arpa.2022-0070-RA ↗
6. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease10.1038/nrclinonc.2016.66 ↗
7. Tailored therapies for triple-negative breast cancer: current landscape and future perceptions10.1007/s00210-025-03896-4 ↗
8. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline10.1200/JCO.20.03399 ↗
9. Triple-negative breast cancer therapeutic resistance: where is the Achilles' heel?10.1016/j.canlet.2020.10.016 ↗
10. Epigenetic modulations in breast cancer: An emerging paradigm in therapeutic implications10.31083/j.fbl2908287 ↗
11. Breast cancer: an up-to-date review and future perspectives10.1002/cac2.12358 ↗
12. Advances in systemic therapies for triple negative breast cancer10.1136/bmj-2022-071674 ↗
13. Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer10.3390/ijms232314937 ↗
14. Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer10.1016/j.biomaterials.2021.120847 ↗
15. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release10.1016/j.addr.2024.115239 ↗
16. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics10.1016/j.cell.2018.02.052 ↗
17. NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update10.1093/nar/gkad965 ↗
18. Syndecan-1 and its expanding list of contacts10.1089/wound.2014.0555 ↗
19. CircKIF4A combines EIF4A3 to stabilize SDC1 expression to activate c-src/FAK and promotes TNBC progression10.1016/j.cellsig.2023.110690 ↗
20. Role of tumor-associated macrophages in breast cancer immunotherapy
21. Syndecan-1 as an immunogene in triple-negative breast cancer: regulation tumor-infiltrating lymphocyte in the tumor microenviroment and EMT by TGFb1/Smad pathway10.1186/s12935-023-02917-7 ↗
22. Defining human insulin-like growth factor I gene regulation10.1152/ajpendo.00212.2016 ↗
23. IGF1 receptor signaling pathways10.1530/JME-17-0311 ↗
24. Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesis10.3389/fendo.2022.926210 ↗
25. β-elemene induced apoptosis and senescence of triple-negative breast cancer cells through IGF1/IGF1R pathway10.1016/j.tice.2022.101914 ↗
26. Recent update on IGF-1/IGF-1R signaling axis as a promising therapeutic target for triple-negative breast cancer10.1016/j.prp.2024.155620 ↗
27. Epigenetics of SFRP1: the dual roles in human cancers10.3390/cancers12020445 ↗
28. Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/Wnt/β-catenin signaling axis10.1007/s00018-022-04295-1 ↗
29. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling10.1186/1476-4598-13-174 ↗
30. SDC1 promotes cisplatin resistance in hepatic carcinoma cells via PI3K-AKT pathway10.1007/s13577-020-00362-6 ↗
31. Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer10.1038/bjc.2014.493 ↗
32. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer10.1016/j.urolonc.2018.03.010 ↗
33. Chinese society of clinical oncology (CSCO) breast cancer guidelines 202410.21037/tbcr-24-31 ↗
34. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial10.1016/S0140-6736(19)32222-6 ↗
35. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics10.1016/j.gendis.2022.02.007 ↗
36. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial10.1186/s12885-023-10768-8 ↗
37. The art and science of molecular docking10.1146/annurev-biochem-030222-120000 ↗
38. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management10.1038/s41598-023-40160-2 ↗
39. Spatial reconstruction of single-cell gene expression data10.1038/nbt.3192 ↗
40. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics10.1126/science.aaf2403 ↗
41. Single-cell RNA sequencing in breast cancer: understanding tumor heterogeneity and paving roads to individualized therapy10.1002/cac2.12078 ↗
42. Dynamics of gene expression in single root cells of Arabidopsis thaliana10.1105/tpc.18.00785 ↗
43. Deciphering cell-cell interactions and communication from gene expression10.1038/s41576-020-00292-x ↗
44. Tumor immune microenvironment (TIME) to enhance antitumor immunity10.1186/s40001-023-01125-3 ↗
45. Tumor-targeted nano-delivery system of therapeutic RNA10.1039/D1MH01969D ↗
46. In situ self-assembling Au-DNA complexes for targeted cancer bioimaging and inhibition10.1073/pnas.1915512116 ↗
47. Bio-assembled smart nanocapsules for targeted delivery of KRAS shRNA and cancer cell bioimage
48. Baiting bacteria with amino acidic and peptidic corona coated defect-engineered antimicrobial nanoclusters for optimized wound healing
49. Reprogramming of cholesterol metabolism in tumor-associated macrophages10.1039/D5TB00236B ↗
50. Advance of nano anticancer therapies targeted on tumor-associated macrophages10.1016/j.ccr.2021.214126 ↗
51. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants10.1126/science.abj4176 ↗
52. Biosynthesized gold nanoclusters and iron complexes as scaffolds for multimodal cancer bioimaging10.1002/smll.201602526 ↗
53. Ten years of anti-vascular endothelial growth factor therapy10.1038/nrd.2015.17 ↗
54. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions10.1016/j.ijbiomac.2022.09.129 ↗
55. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease10.1093/jb/mvq121 ↗
56. Fibroblast growth factor signalling: from development to cancer10.1038/nrc2780 ↗
57. New developments in the biology of fibroblast growth factors
58. The exosome journey: from biogenesis to uptake and intracellular signalling10.1186/s12964-021-00730-1 ↗
59. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression10.1093/carcin/bgp001 ↗
60. Suppressing Syndecan-1 shedding ameliorates intestinal epithelial inflammation through inhibiting NF-κB pathway and TNF-α10.1155/2016/6421351 ↗
61. Syndecan-1 shedding by matrix Metalloproteinase-9 signaling regulates alveolar epithelial tight junction in lipopolysaccharide-induced early acute lung injury10.2147/JIR.S331020 ↗
62. Metabolic reprogramming in cancer and senescence
63. Cellular elasticity in cancer: a review of altered biomechanical features10.1039/D4TB00328D ↗
64. An aged immune system drives senescence and ageing of solid organs10.1038/s41586-021-03547-7 ↗
65. CD8(+) T cell exhaustion and cancer immunotherapy10.1016/j.canlet.2022.216043 ↗
66. CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours10.1038/s41586-023-06199-x ↗
67. New insights into M1/M2 macrophages: key modulators in cancer progression10.1186/s12935-021-02089-2 ↗
68. M1/M2 macrophages and their overlaps - myth or reality?10.1042/CS20220531 ↗
69. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance10.1038/s41698-024-00522-z ↗
70. Tumor-infiltrating mast cells stimulate ICOS(+) regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression10.1016/j.jare.2023.04.013 ↗
71. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy10.1038/s41467-020-20600-7 ↗
72. Cancer associated fibroblasts: an essential role in the tumor microenvironment10.3892/ol.2017.6497 ↗
73. Cancer-associated fibroblasts facilitate premetastatic niche formation through lncRNA SNHG5-mediated angiogenesis and vascular permeability in breast cancer10.7150/thno.74753 ↗
74. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo10.1007/s10456-013-9381-6 ↗
75. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer10.1136/jitc-2020-001341 ↗
76. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling10.1038/bjc.2013.768 ↗
77. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer10.1016/j.immuni.2021.04.021 ↗